Advances in the classification and treatment of mastocytosis: current status and outlook toward the future
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4507883
Author(s) Valent, Peter; Akin, Cem; Hartmann, Karin; Nilsson, Gunnar; Reiter, Andreas; Hermine, Olivier; Sotlar, Karl; Sperr, Wolfgang R.; Escribano, Luis; George, Tracy I.; Kluin-Nelemans, Hanneke C.; Ustun, Celalettin; Triggiani, Massimo; Brockow, Knut; Gotlib, Jason; Orfao, Alberto; Schwartz, Lawrence B.; Broesby-Olsen, Sigurd; Bindslev-Jensen, Carsten; Kovanen, Petri T.; Galli, Stephen J.; Austen, K. Frank; Arber, Daniel A.; Horny, Hans-Peter; Arock, Michel; Metcalfe, Dean D.
Author(s) at UniBasel Hartmann, Karin
Year 2017
Title Advances in the classification and treatment of mastocytosis: current status and outlook toward the future
Journal Cancer Research
Volume 77
Number 6
Pages / Article-Number 1261-1270
Mesh terms Disease Progression; Humans; Mastocytosis, classification, therapy
Abstract Mastocytosis is a term used to denote a heterogeneous group of conditions defined by the expansion and accumulation of clonal (neoplastic) tissue mast cells in various organs. The classification of the World Health Organization (WHO) divides the disease into cutaneous mastocytosis, systemic mastocytosis, and localized mast cell tumors. On the basis of histomorphologic criteria, clinical parameters, and organ involvement, systemic mastocytosis is further divided into indolent systemic mastocytosis and advanced systemic mastocytosis variants, including aggressive systemic mastocytosis and mast cell leukemia. The clinical impact and prognostic value of this classification has been confirmed in numerous studies, and its basic concept remains valid. However, refinements have recently been proposed by the consensus group, the WHO, and the European Competence Network on Mastocytosis. In addition, new treatment options are available for patients with advanced systemic mastocytosis, including allogeneic hematopoietic stem cell transplantation and multikinase inhibitors directed against KIT D816V and other key signaling molecules. Our current article provides an overview of recent advances in the field of mastocytosis, with emphasis on classification, prognostication, and emerging new treatment options in advanced systemic mastocytosis.; Cancer Res; 77(6); 1261-70. ©2017 AACR; .
Publisher AMER ASSOC CANCER RESEARCH
ISSN/ISBN 1538-7445
edoc-URL https://edoc.unibas.ch/70876/
Full Text on edoc No
Digital Object Identifier DOI 10.1158/0008-5472.CAN-16-2234
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/28254862
ISI-Number WOS:000396845600003
Document type (ISI) Journal Article, Review
 
   

MCSS v5.8 PRO. 0.430 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
10/08/2020